Predix Pharmaceuticals Receives Patent On Novel 5-HT Receptor Antagonists And The Related Treatment Of Disorders Associated With Serotonin Action

LEXINGTON, Mass.--(BUSINESS WIRE)--May 3, 2006--Predix Pharmaceuticals, who recently announced a definitive agreement to merge with EPIX Pharmaceuticals (Nasdaq: EPIX - News), announced today that the United States Patent and Trademark Office has issued to Predix patent number 7,030,240 B2 'piperidinylamino-thieno(2,3-d)pyridimine compounds'. This patent includes claims to the composition of matter, synthesis and use of 5-HT receptor antagonists in the treatment, modulation or prevention of physiological conditions associated with serotonin action, such as in treating vascular disorders (e.g., angina, pulmonary hypertension, migraine). Predix's novel 5-HT2B antagonist, PRX-08066, is covered under this patent.

Back to news